Altimmune, Inc. (ALT): A Bull Case Theory
We came across a bullish thesis on Altimmune, Inc. (ALT) on WallStreetBets subreddit page by Old-Pomegranate3634. In this article, we will summarize the bulls’ thesis on ALT.
Altimmune Inc. (ALT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 0 | $0 | -100% | 0% |
| 2. | Renaissance Technologies Jim Simons | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.88 | 300 | Director | 29,785 | 2023-08-15 | Filing | |
| $4.27 | 9,000 | Director | 29,484 | 2023-03-23 | Filing | |
| $4.31 | 10,000 | Officer | 22,010 | 2023-03-24 | Filing | |
| $4.22 | 10,000 | Officer | 33,311 | 2023-03-23 | Filing | |
| $8.00 | 1,000 | Director | 20,012 | 2022-06-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.88 | 8,184 | Director | 55,524 | 2024-08-19 | Filing | |
| $6.93 | 7,827 | Director | 41,958 | 2024-08-19 | Filing | |
| $15.00 | 2,714 | Director | 2,771 | 2022-08-12 | Filing | |
| $15.01 | 20,000 | Director | 8,498 | 2022-12-22 | Filing | |
| $20.02 | 20,000 | Officer, Director | 236,797 | 2022-08-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript
Operator: Good day, ladies and gentlemen and welcome to Altimmune Inc. First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Altimmune Inc. Full Year and Fourth Quarter 2023 Financial Results Conference Call.
16 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the 16 most promising long-term stocks according to analysts.
13 Hot Penny Stocks To Buy According to Hedge Funds
The overall market optimism helped by expectations that the Fed might start cutting interest rates in 2024 is helping riskier assets and equities, including small-cap stocks, penny stocks and cryptocurrencies...
Altimmune, Inc. (NASDAQ:ALT) Q3 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Altimmune, Inc. Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
5 Best Biotech Penny Stocks to Buy Now
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) ranks 5th in our list of the best biotech penny stocks to buy now according to hedge funds. Ginkgo Bioworks Holdings, Inc.
10 Most Promising Penny Stocks According to Analysts
Innovation is what drives human societies forward. Major companies of today were once small companies working on innovative and disruptive ideas. A 2019 report by T.
Altimmune, Inc. (NASDAQ:ALT) Q2 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Altimmune, Inc. Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10 Best Rated Penny Stocks to Buy According to Analysts
Investing in small companies, penny stocks, micro-cap or even small-cap companies went out of fashion as soon as the financial markets started to take a beating amid interest rate hikes.
Billionaire Hedge Funds
